FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170468317> ?p ?o ?g. }

• W2170468317 endingPage "563" @default.
• W2170468317 startingPage "556" @default.
• W2170468317 abstract "Objective Carbamazepine causes severe cutaneous adverse drug reactions that may be predicted by the presence of the HLA-A*31:01 allele in northern European populations. There is uncertainty as to whether routine testing of patients with epilepsy is cost-effective. We conducted an economic evaluation of HLA-A*31:01 testing from the perspective of the National Health Service (NHS) in the United Kingdom. Methods A short-term, decision analytic model was developed to estimate the outcomes and costs associated with a policy of routine testing (with lamotrigine prescribed for patients who test positive) versus the current standard of care, which is carbamazepine prescribed without testing. A Markov model was used to estimate total costs and quality-adjusted life-years (QALYs) over a lifetime to account for differences in drug effectiveness and the long-term consequences of adverse drug reactions. Results Testing reduced the expected rate of cutaneous adverse drug reactions from 780 to 700 per 10,000 patients. The incremental cost-effectiveness ratio for pharmacogenetic testing versus standard care was £12,808 per QALY gained. The probability of testing being cost-effective at a threshold of £20,000 per QALY was 0.80, but the results were sensitive to estimated remission rates for alternative antiepileptic drugs (AEDs). Significance Routine testing for HLA-A*31:01 in order to reduce the incidence of cutaneous adverse drug reactions in patients being prescribed carbamazepine for epilepsy is likely to represent a cost-effective use of health care resources." @default.
• W2170468317 created "2016-06-24" @default.
• W2170468317 creator A5001722721 @default.
• W2170468317 creator A5005069325 @default.
• W2170468317 creator A5006847944 @default.
• W2170468317 creator A5070376982 @default.
• W2170468317 creator A5072175945 @default.
• W2170468317 creator A5077741051 @default.
• W2170468317 date "2015-02-26" @default.
• W2170468317 modified "2023-10-14" @default.
• W2170468317 title "Cost-effectiveness of screening for<i>HLA-A*31:01</i>prior to initiation of carbamazepine in epilepsy" @default.
• W2170468317 cites W1584473399 @default.
• W2170468317 cites W1971946342 @default.
• W2170468317 cites W1984185385 @default.
• W2170468317 cites W2044605108 @default.
• W2170468317 cites W2044645437 @default.
• W2170468317 cites W2051267089 @default.
• W2170468317 cites W2059973110 @default.
• W2170468317 cites W2067117895 @default.
• W2170468317 cites W2069763668 @default.
• W2170468317 cites W2104572372 @default.
• W2170468317 cites W2104951811 @default.
• W2170468317 cites W2105178715 @default.
• W2170468317 cites W2106203584 @default.
• W2170468317 cites W2108686931 @default.
• W2170468317 cites W2111819588 @default.
• W2170468317 cites W2122472502 @default.
• W2170468317 cites W2128377197 @default.
• W2170468317 cites W2138521331 @default.
• W2170468317 cites W2139992285 @default.
• W2170468317 cites W2143025931 @default.
• W2170468317 cites W2147974822 @default.
• W2170468317 cites W2166610199 @default.
• W2170468317 cites W2167749652 @default.
• W2170468317 cites W2168120312 @default.
• W2170468317 doi "https://doi.org/10.1111/epi.12937" @default.
• W2170468317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26046144" @default.
• W2170468317 hasPublicationYear "2015" @default.
• W2170468317 type Work @default.
• W2170468317 sameAs 2170468317 @default.
• W2170468317 citedByCount "58" @default.
• W2170468317 countsByYear W21704683172015 @default.
• W2170468317 countsByYear W21704683172016 @default.
• W2170468317 countsByYear W21704683172017 @default.
• W2170468317 countsByYear W21704683172018 @default.
• W2170468317 countsByYear W21704683172019 @default.
• W2170468317 countsByYear W21704683172020 @default.
• W2170468317 countsByYear W21704683172021 @default.
• W2170468317 countsByYear W21704683172022 @default.
• W2170468317 countsByYear W21704683172023 @default.
• W2170468317 crossrefType "journal-article" @default.
• W2170468317 hasAuthorship W2170468317A5001722721 @default.
• W2170468317 hasAuthorship W2170468317A5005069325 @default.
• W2170468317 hasAuthorship W2170468317A5006847944 @default.
• W2170468317 hasAuthorship W2170468317A5070376982 @default.
• W2170468317 hasAuthorship W2170468317A5072175945 @default.
• W2170468317 hasAuthorship W2170468317A5077741051 @default.
• W2170468317 hasBestOaLocation W21704683171 @default.
• W2170468317 hasConcept C104317684 @default.
• W2170468317 hasConcept C112930515 @default.
• W2170468317 hasConcept C118552586 @default.
• W2170468317 hasConcept C126322002 @default.
• W2170468317 hasConcept C135763542 @default.
• W2170468317 hasConcept C177713679 @default.
• W2170468317 hasConcept C185592680 @default.
• W2170468317 hasConcept C187212893 @default.
• W2170468317 hasConcept C197934379 @default.
• W2170468317 hasConcept C2778186239 @default.
• W2170468317 hasConcept C2778802184 @default.
• W2170468317 hasConcept C2779253243 @default.
• W2170468317 hasConcept C2780673598 @default.
• W2170468317 hasConcept C3019080777 @default.
• W2170468317 hasConcept C55493867 @default.
• W2170468317 hasConcept C55775858 @default.
• W2170468317 hasConcept C64332521 @default.
• W2170468317 hasConcept C71924100 @default.
• W2170468317 hasConceptScore W2170468317C104317684 @default.
• W2170468317 hasConceptScore W2170468317C112930515 @default.
• W2170468317 hasConceptScore W2170468317C118552586 @default.
• W2170468317 hasConceptScore W2170468317C126322002 @default.
• W2170468317 hasConceptScore W2170468317C135763542 @default.
• W2170468317 hasConceptScore W2170468317C177713679 @default.
• W2170468317 hasConceptScore W2170468317C185592680 @default.
• W2170468317 hasConceptScore W2170468317C187212893 @default.
• W2170468317 hasConceptScore W2170468317C197934379 @default.
• W2170468317 hasConceptScore W2170468317C2778186239 @default.
• W2170468317 hasConceptScore W2170468317C2778802184 @default.
• W2170468317 hasConceptScore W2170468317C2779253243 @default.
• W2170468317 hasConceptScore W2170468317C2780673598 @default.
• W2170468317 hasConceptScore W2170468317C3019080777 @default.
• W2170468317 hasConceptScore W2170468317C55493867 @default.
• W2170468317 hasConceptScore W2170468317C55775858 @default.
• W2170468317 hasConceptScore W2170468317C64332521 @default.
• W2170468317 hasConceptScore W2170468317C71924100 @default.
• W2170468317 hasIssue "4" @default.
• W2170468317 hasLocation W21704683171 @default.
• W2170468317 hasLocation W21704683172 @default.
• W2170468317 hasOpenAccess W2170468317 @default.

• next